COMPANY
PhotoPharmics, Inc.
Timeline
- Raise Private equity round — Series B Extension: $6M (total, as published), announced Apr 18, 2025. Source: company's own press page. source ↗
- Trial start Not phased (device or behavioral study): DB RCT for Specialized Phototherapy in Parkinson's Disease. source ↗
- Trial start Not phased (device or behavioral study): Heterodyned Whole-Body Vibration in Treatment of Opioid Withdrawal-Induced Anxiety source ↗
- Trial start Not phased (device or behavioral study): Efficacy Study of Light Therapy as an Adjunctive Treatment for Parkinson's Disease source ↗
Funding
- Private equity round — Series B Extension: $6M (total, as published), announced Apr 18, 2025. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04453033 | DB RCT for Specialized Phototherapy in Parkinson's Disease. | Not phased (device or behavioral study) | Completed | Feb 26, 2024 | May 30, 2026 (actual) |
| NCT05056753 | Heterodyned Whole-Body Vibration in Treatment of Opioid Withdrawal-Induced Anxiety | Not phased (device or behavioral study) | Completed | Jan 20, 2022 | Jun 1, 2023 (actual) |
| NCT02175472 | Efficacy Study of Light Therapy as an Adjunctive Treatment for Parkinson's Disease | Not phased (device or behavioral study) | Completed | 2014-06 | 2016-10 (actual) |
NIH awards 2
- NIH award 1R42DA060644-01 FY2024: $319,278 awarded for that fiscal year; activity R42 (STTR); PI ADAMS, DANIEL NATHAN; recipient as written: PHOTOPHARMICS, INC., Lehi, UT. Amelioration of opioid use disorder with het source ↗
- NIH award 1R41DA053083-01A1 FY2021: $319,976 awarded for that fiscal year; activity R41 (STTR); PI ADAMS, DANIEL NATHAN; recipient as written: PHOTOPHARMICS, INC., Lehi, UT. Amelioration of opioid withdrawal-induced source ↗